首页> 外文期刊>Paediatric anaesthesia >Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice.
【24h】

Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice.

机译:在儿科临床药理学中使用基于生理学的药代动力学模型的复苏:结合生物学要素的知识并发转移,以及在药物开发和临床实践中的适用性增加。

获取原文
获取原文并翻译 | 示例
           

摘要

AIMS AND OBJECTIVES: (i) To describe an example of the development work required for building a 'pediatric physiologically based pharmacokinetic' (P-PBPK) model (Simcyp Pediatric ADME Simulator), (ii) to replicate pediatric clinical studies and undertake theoretical studies to show the potential applications of mechanistic PBPK in pediatric drug clinical investigation and practice, with emphasis on pediatric anesthesia. BACKGROUND: PBPK models draw together the physiological and biochemical information that determine drug absorption, distribution, metabolism, and excretion and then link them in a physiologically realistic 'systems' model. Incorporating the emerging additional information on developmental physiology and biochemistry has resulted in the creation of P-PBPK. There has been a renewed interest in the application of such modeling by the pharmaceutical industry to improve the efficiency of drug development, especially in populations where designing and conducting clinical studies is more challenging, such as pediatric patients. METHODS: P-PBPK was used to simulate a number of published clinical studies and clinical case scenarios with the aim of highlighting the potential applications. RESULTS: Changing the P-PBPK model parameters in a number of 'what if' simulations were used to explore the likely underlying reasons for observed pharmacokinetic (PK) behavior of drugs in critically ill children. In addition, the use of P-PBPK models to predict complex drug-drug interactions (DDI) highlighted disparities with adult populations. DISCUSSION: The examples highlight the use of prior knowledge of in vitro drug attributes and biology of the system (human body) to simulate PK and multiple DDI scenarios not infrequently encountered in critically ill pediatric patients.
机译:目的和目标:(i)描述建立“儿科基于生理学的药代动力学”(P-PBPK)模型(Simcyp Pediatric ADME Simulator)所需的开发工作的示例,(ii)复制儿科临床研究并进行理论研究展示了机械性PBPK在儿科药物临床研究和实践中的潜在应用,重点是儿科麻醉。背景:PBPK模型将确定药物吸收,分布,代谢和排泄的生理和生化信息汇总在一起,然后将它们链接到生理上现实的“系统”模型中。结合新出现的有关发育生理学和生物化学的其他信息,导致了P-PBPK的产生。制药业对这种模型的应用已经产生了新的兴趣,以提高药物开发的效率,特别是在设计和进行临床研究更具挑战性的人群中,例如儿科患者。方法:P-PBPK用于模拟许多已发表的临床研究和临床病例,旨在突出潜在的应用。结果:在许多“假设分析”模拟中更改了P-PBPK模型参数,以探讨观察到的危重儿童药物的药代动力学(PK)行为的可能潜在原因。此外,使用P-PBPK模型预测复杂的药物-药物相互作用(DDI)突显了与成人人群的差异。讨论:这些示例强调了使用体外药物属性和系统生物学(人体)的先验知识来模拟重症儿科患者很少遇到的PK和多种DDI情况。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号